Xianzhang Bu

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 5

Top Topics

Cross Sectional

Epithelial Mesenchymal Transition

Top Venues

Chemical communications (Cambridge, England)

Journal of medicinal chemistry

Nature communications

ACS medicinal chemistry letters

This page only lists publications with an associated author ORCID identifier.

Publications

Xiaoquan Wang, Youqiao Wang, Anqi Cao, Qinhong Luo, Daoyuan Chen, Weiqi Zhao, Jun Xu, Qinkai Li, Xianzhang Bu, Jun-Min Quan
Development of cyclopeptide inhibitors of cGAS targeting protein-DNA interaction and phase separation. Nature communications 14 (1) (2023)
Yunzhi Li, Chaoying Jin, Huiying Xu, Weijian Wu, Youqiao Wang, Jiaxin Wu, Tingyu Liu, Guohui Wan, Xin Yue, Xianzhang Bu
Identification of 2-Benzylidene-tetralone Derivatives as Highly Potent and Reversible Firefly Luciferase Inhibitors. ACS medicinal chemistry letters 13 (2) (2022)
Yanqiao Feng, Hui Su, Yunzhi Li, Chunxiang Luo, Huiying Xu, Youqiao Wang, Haixia Sun, Guohui Wan, Binhua Zhou, Xianzhang Bu
Degradation of intracellular TGF-β1 by PROTACs efficiently reverses M2 macrophage induced malignant pathological events. Chemical communications (Cambridge, England) 56 (19) (2020)
Haixia Sun, Daoyuan Chen, Siyue Zhan, Weijian Wu, Huiying Xu, Chunxiang Luo, Hui Su, Yanqiao Feng, Weiyan Shao, Arabella Wan, Binhua Zhou, Guohui Wan, Xianzhang Bu
Design and Discovery of Natural Cyclopeptide Skeleton Based Programmed Death Ligand 1 Inhibitor as Immune Modulator for Cancer Therapy. Journal of medicinal chemistry 63 (19) (2020)
Gesi Wen, Wenjing Qin, Daoyuan Chen, Youqiao Wang, Xin Yue, Ziyi Liu, Yingnan Cao, Jun Du, Binhua Zhou, Xianzhang Bu
Stabilizing the monomeric amyloid-β peptide by tyrocidine A prevents and reverses amyloidogenesis without the accumulation of oligomers. Chemical communications (Cambridge, England) 53 (27) (2018)